Oncology Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Galapagos after u. S. Drug maker gilead doubles its stake with a 5. 1 billion investment. And rallies after being awarded 5. 8 billion in damages relating to a joint venture in pakistan and as the race heats up for the next managing director of the imf, the fund hosts an event on central and Eastern Europe. Ill be speaking shortly to the the deputy managing director of the fund well good morning, and happy monday i want to take you to some of the price Market Action that weve had over the last couple of hours or so on friday we had wall street close at record highs, but the news of the last 24...

Everyones information there will not be endorsements from the panelists today one important thing i want to clear up because i think it is important for context of this discussion is that the impression you have in organizations in working on this because in washington d. C. People say on the 6 00 news on the sunday talk shows where is the compromise . Where are the people in the middle that can split the baby and come up with legislation . I think that youre going to hear loud and clear from us but is this about compromise or is this about working towards shared values of principled people on...

Syria, in that vacuum that has been created and they could amass more arms and resources there. Phil mattingly has been following the administrations response. What was president obamas goal and sending the secretary of state to the middle east . The u. S. Government and the president look at this as dual track. There is the diplomatic side of things. That is where the secretary of state comes in. He met with the Prime Minister this morning, the top shiite leader in the country. He is also meeting with the speaker of the parliament, the top sunni leader in iraq. What they are trend to do is pu...

Carlos Arteaga, MD, discusses the resistance to CDK4/g inhibitors in hormone receptor–positive breast cancer.

PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.